Medical Researchers Seek Federal Approval to Test Plant Compound for Brain Damage and Trauma
Scottsdale, Wednesday, 29 July 2026.
Scottsdale Research Institute submitted an FDA application for ibogaine hydrochloride, aiming to initiate 2027 clinical trials to restore neural function in veterans and civilians facing severe psychological trauma.
Regulatory Filing Confirmed for Neuroplastogen
The Scottsdale Research Institute (SRI) has formally submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Ibogaine Hydrochloride (Ibogaine HCl) [1]. This submission, announced on July 28, 2026, marks a critical regulatory milestone for the investigational neuroplastogen designed to promote neuroplasticity and restore neural function [1]. The application targets treatments for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and opioid use disorder, receiving the IND assignment number 183727 [1]. SRI utilizes a dataset exceeding 1,000 patients from its own licensed clinics to analyze ibogaine safety profiles prior to this federal submission [2].
Clinical Trial Timeline and Partnerships
Pending FDA and Institutional Review Board authorization, SRI expects to initiate a Phase 1 clinical trial in early 2027 to assess safety and tolerability in military veterans and civilians [1]. The institute is partnering with Brian Anderson, M.D., an Associate Professor at the University of California, San Francisco, to advance the clinical development program [1]. The active pharmaceutical ingredient is supplied by Psygen (Canada) using SRI’s DEA Schedule I Importer Registration [1]. This timeline follows a period of accelerated regulatory interest, with a White House executive order in April 2026 mandating that the FDA prioritize the review of psychedelic compounds [2].
Broader Industry Landscape and Funding
The regulatory environment has shifted significantly following a March 2026 announcement where Texas committed approximately $100 million to a state-funded research program led by UTHealth Houston and UTMB Galveston [2]. This initiative spans a two-year period, and Mississippi and West Virginia have subsequently approved legislation to join this research coalition [2]. In terms of market competition, DemeRx Inc. holds the first FDA IND application for an ibogaine-class compound, which is currently undergoing multi-site Phase II/III evaluation for opioid use disorder [2]. The time elapsed between the Texas funding announcement in March 2026 and the SRI filing in July 2026 is approximately 4 months, indicating rapid sector movement [2][1].
Safety Protocols and Outlook
Clinical safety protocols for ibogaine administration mandate pre-treatment 12-lead EKG, electrolyte correction, and continuous cardiac monitoring to mitigate risks such as QTc interval prolongation [2]. Observational data indicates that serious adverse cardiac events are rare when established safety precautions are strictly followed, though documented literature confirms the occurrence of deaths associated with ibogaine administration [2]. Future Phase IV post-market surveillance will likely require FDA-mandated Risk Evaluation and Mitigation Strategy (REM S) conditions, including certified prescriber training [2]. SRI expressed appreciation for the FDA’s acceptance of their IND application for review, noting this represents an important step toward rigorously evaluating ibogaine hydrochloride under the FDA’s regulatory framework [1].